We are live on ! Find out more
GP

Geneva Partners Portfolio holdings

AUM $375M
1-Year Est. Return 131.24%
This Fund
S&P 500
This Quarter Est. Return
+63.68%
1 Year Est. Return
+131.24%
3 Year Est. Return
+400.69%
5 Year Est. Return
+687.84%
10 Year Est. Return
AUM
$375M
AUM Growth
+$167M
Cap. Flow
+$78.9M
Cap. Flow %
21.04%
Top 10 Hldgs %
41.06%
Holding
81
New
18
Increased
32
Reduced
22
Closed
6

Top Buys

Rank Stock Value
1
MRVL icon
Marvell Technology
MRVL
+$13.6M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$12.8M
3
TER icon
Teradyne
TER
+$10.8M
4
GLW icon
Corning
GLW
+$9.04M
5
BE icon
Bloom Energy
BE
+$7.64M

Sector Composition

Rank Sector Weight
1 Technology 41.44%
2 Miscellaneous 22.43%
3 Industrials 20.38%
4 Communication Services 5.93%
5 Energy 4.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AAOI icon
76
Applied Optoelectronics
AAOI
$8.09B
-29,515
Closed -$2.5M
HSY icon
77
Hershey
HSY
$34.2B
-12,932
Closed -$2.69M
ORLY icon
78
O'Reilly Automotive
ORLY
$68.9B
-37,858
Closed -$3.49M
VHT icon
79
Vanguard Health Care ETF
VHT
$19B
-29,538
Closed -$8.04M
WM icon
80
Waste Management
WM
$86.8B
-1,387
Closed -$319K
SNDK
81
Sandisk
SNDK
$224B
-1,665
Closed -$1.06M

Similar funds

Geneva Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Geneva Partners held 81 positions worth $375M, up 80% from $208M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Geneva Partners deployed $78.9M of net new capital in Q2 2026, opening 18 new positions and adding to 32 existing holdings. Its largest new stake was Marvell Technology: 68,048 shares worth $20.3M.

By sector, the portfolio is most concentrated in Technology at 41% of assets, up from 24% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Eli Lilly, an estimated $3.76M trimmed.

  • Geneva Partners's largest Q2 2026 buy was Marvell Technology: 68,048 shares worth $20.3M.
  • Geneva Partners added most to Dell in Q2 2026, an estimated $4.08M increase.
  • Geneva Partners's biggest Q2 2026 reduction was Eli Lilly, cutting an estimated $3.76M.
  • Geneva Partners fully exited Vanguard Health Care ETF in Q2 2026, selling an estimated $8.04M.
  • Geneva Partners's ten largest holdings make up 41% of its $375M portfolio in Q2 2026.
  • Geneva Partners opened 18 new positions and closed 6 in Q2 2026.
  • Geneva Partners's portfolio value rose 80% quarter-over-quarter to $375M.

Based on Geneva Partners's 13F filing for Q2 2026, filed 10 Aug 2026.